2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

3251 Efficacy and safety of LTI214, a novel CD33 directed MHC class II engager immunotherapy, in a Trp53 deficient and treatment resistant model of acute myeloid leukemia (AML)

Leticia Reyes, Lena Golick2, Christopher Nguyen3, Reeder Robinson, PhD4, Sandeep Gupta5, Jayastu Senapati, MBBS, MD, DM6, Nathan Dolloff, PhD7
1 Medical University of South Carolina, Charleston, South Carolina, United States
2 Medical University of South Carolina, Charleston, South Carolina, United States
3 Medical University of South Carolina, Charleston, South Carolina, United States
4 Medical University of South Carolina, Charleston, South Carolina, United States
5 Leukogene Therapeutics, Inc, Charleston, South Carolina, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 Medical University of South Carolina, Charleston, South Carolina, United States

Management of high-risk AML remains challenging due to the absence of targetable genomic aberrations and an immunologically cold phenotype that is resistant to new immune therapies. Sialic acid binding Ig-like lectin 3 (CD33) is a widely recognized myeloid-restricted cell surface protein. CD33 is expressed at high density on leukemic blasts across the subclasses of AML, making it a potentially genomic-agnostic therapeutic target. However, CD33-targeted T cell-based immunotherapies and the CD33-specific antibody-drug conjugate (ADC), gemtuzumab ozogamicin, have produced only modest clinical benefit in favorable risk AML with dose-limiting toxicities. To address this, we developed LTI-214, a recombinant Major Histocompatibility Complex class II (MHCII) engager molecule linked to an optimized segment of the CD33 extracellular domain. LTI-214 delivers CD33 directly to antigen presenting cells (APCs), forcing CD33-specific immunity using the natural antigen presentation machinery independent of HLA polymorphisms and the need for speculative antigen design methods. MHCII is a central regulator of antigen presentation, and essential for activation of the full spectrum of adaptive immunity from CD4+ and CD8+ T cells, B cells, NK cells, macrophages, and others. Our rationale was that a fully integrated CD33-specific immune response guided by MHCII could uncover previously unrealized therapeutic benefit for the treatment of AML.

To demonstrate the therapeutic potential of LTI-214, we used the murine C1498 AML xenotransplant model in syngeneic and immunocompetent C57BL/6 mice. We show that C1498 cells are Trp53-deficient and resistant to standard chemotherapy, hypomethylating agents, and the Bcl-2 inhibitor, venetoclax, suggesting they model one of the most challenging subtypes of AML in humans. LTI-214 significantly improved animal survival in prophylactic and therapeutic treatment settings from 30 to 82 days (P<0.0001, N=15) and 45 days (P<0.0001, N=10), respectively, despite the aggressive disease timelines presented by these models. Treatment induced a robust polyclonal anti-CD33 humoral response characterized by induction of the full repertoire of immunoglobulin isotypes and selection and expansion of antigen-specific T cells. Immunopeptidomics analysis showed that MHCII engagement induced internalization of LTI-214 and the loading of new MHCII molecules with multiple CD33 peptides spanning both IgV and IgC domains of CD33. Efficacy was shown to be CD4+ and CD8+ T cell dependent, and the immune response was elicited against both the full length and spliced version of CD33, unlike anti-CD33 mAbs that bind exclusively to the IgV domain. Combined treatment with LTI-214 and venetoclax/5-Azacytidine showed significantly greater efficacy than LTI-214 or venetoclax/5-Azacytidine alone, suggesting a clinical pathway in r/r AML or newly diagnosed AML in patients unfit to receive high dose chemotherapy. By RMST analysis, the combination was highly synergistic, providing an additional 34.7 survival days beyond the calculated additive benefit level. C1498 cells also express PD-L1 and LTI-214 was synergistic with anti-PD-1 therapy even though anti-PD-1 therapy alone showed limited efficacy. LTI-214 exhibited a favorable safety profile in fully murine and CD34+ cord blood stem cell humanized mouse models. Safety signals showed no evidence of cytokine release syndrome or organ toxicity, and minimal impact on normal hematopoiesis at concentrations 40-fold higher than the efficacious dose. These experiments demonstrate the potential of LTI-214, a novel MHCII-engaging immunotherapy targeting CD33 for the treatment of AML, including highly aggressive p53-deficient disease subclasses.

Nathan Dolloff, PhD: Leukogene Therapeutics Inc - Current equity holder in private company; Leukogene Therapeutics Inc - Current Employment